Regional Differences in Efficacy, Safety, and Biomarkers for Second-Line Axitinib in Patients with Advanced Hepatocellular Carcinoma: From a Randomized Phase II Study | Zendy

Masatoshi Kudo | Zendy; YoonKoo Kang | Zendy; JoongWon Park | Zendy; Shukui Qin | Zendy; Yoshitaka Inaba | Zendy; Éric Assenat | Zendy; Yoshiko Umeyama | Zendy; María José Lechuga | Zendy; Olga Valota | Zendy; Yosuke Fujii | Zendy; JeanFrançois Martini | Zendy; James A. Williams | Zendy; Shuntaro Obi | Zendy

Open Access

Regional Differences in Efficacy, Safety, and Biomarkers for Second-Line Axitinib in Patients with Advanced Hepatocellular Carcinoma: From a Randomized Phase II Study

Author(s) -

Masatoshi Kudo,

YoonKoo Kang,

JoongWon Park,

Shukui Qin,

Yoshitaka Inaba,

Éric Assenat,

Yoshiko Umeyama,

María José Lechuga,

Olga Valota,

Yosuke Fujii,

JeanFrançois Martini,

James A. Williams,

Shuntaro Obi

Publication year - 2017

Publication title -

liver cancer

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.916

H-Index - 34

eISSN - 2235-1795

pISSN - 1664-5553

DOI - 10.1159/000484620

Subject(s) - axitinib , medicine , sorafenib , hepatocellular carcinoma , oncology , placebo , subgroup analysis , proportional hazards model , ramucirumab , overall survival , meta analysis , pathology , alternative medicine

An unmet need exists for treatment of patients with advanced hepatocellular carcinoma (HCC) who progress on or are intolerant to sorafenib. A global randomized phase II trial (ClinicalTrial.gov No. NCT01210495) of axitinib, a vascular endothelial growth factor receptor 1-3 inhibitor, in combination with best supportive care (BSC) did not prolong overall survival (OS) over placebo/BSC, but showed improved progression-free survival in some patients. Subgroup analyses were conducted to identify potential predictive/prognostic factors.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research